Kazi Mustafa Mahmud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazi Mustafa Mahmud has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Salman Shakil
Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh
4 shared publications - Mahruba Sultana Niloy
Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh
3 shared publications - Asiful Islam
Department of Biomedical Science and Physiology, School of Pharmacy and Life Sciences, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK
2 shared publications - Annemarie C. Fritz
Department of Chemistry & Biochemistry Texas Tech University Lubbock TX 79409 USA
1 shared publication - Ashraful Hasan
Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh
1 shared publication - Brenda Alfaro
Department of Chemistry & Biochemistry Texas Tech University Lubbock TX 79409 USA
1 shared publication
Latest Publications
- 26 October 2025
- Published by Wiley in Advanced Optical Materials
- Vol. 13 (35)
Multivariable Design of a Minimalist Conjugated Polymer Nanoparticle with Bright NIR‐II Emission
Near‐infrared (NIR) emitting materials underpin emerging medical diagnostics and therapeutic bionanotechnologies. In particular, the NIR‐II window (1000–1700 nm) allows for enhanced penetration depth and image clarity in vivo by minimizing light‐tissue interactions. Organic materials are advantageous due to their synthetic tunability; however, the energy gap law poses fundamental limitations on accessible quantum yields (Φ) due to the exponential increase in nonradiative decay rates as the bandgap narrows. Conjugated polymer nanoparticles (CPNs) offer biocompatibility, photostability, and remarkable absorption cross‐sections (ɛ), the latter of which can offset the reduced Φ of the organic material to afford brilliant emission (ɛ × Φ). Here, a structurally simple, scalable furan‐flanked diketopyrrolopyrrole material (PDFT) with peak emission at 950 nm is investigated, and the role of backbone architecture, molecular weight, and particle size on NIR‐II emission brightness are explored. PDFT CPNs features extraordinary brightness and photostability in solution and in vivo, outperforming indocyanine green and many contemporary NIR‐II emitters. Through rational structural modifications across multiple length scales, the NIR‐II brightness is enhanced >5000× beyond alternative small molecules, featuring a minimum detectable dose of 0.65 n m in vivo. This performance, combined with synthetic accessibility and scalability, positions PDFT as a promising material for NIR‐II bionanotechnologies.
- 26 October 2025
- Published by Wiley in Advanced Optical Materials
- Vol. 13 (35)
Multivariable Design of a Minimalist Conjugated Polymer Nanoparticle with Bright NIR‐II Emission
Near‐infrared (NIR) emitting materials underpin emerging medical diagnostics and therapeutic bionanotechnologies. In particular, the NIR‐II window (1000–1700 nm) allows for enhanced penetration depth and image clarity in vivo by minimizing light‐tissue interactions. Organic materials are advantageous due to their synthetic tunability; however, the energy gap law poses fundamental limitations on accessible quantum yields (Φ) due to the exponential increase in nonradiative decay rates as the bandgap narrows. Conjugated polymer nanoparticles (CPNs) offer biocompatibility, photostability, and remarkable absorption cross‐sections (ɛ), the latter of which can offset the reduced Φ of the organic material to afford brilliant emission (ɛ × Φ). Here, a structurally simple, scalable furan‐flanked diketopyrrolopyrrole material (PDFT) with peak emission at 950 nm is investigated, and the role of backbone architecture, molecular weight, and particle size on NIR‐II emission brightness are explored. PDFT CPNs features extraordinary brightness and photostability in solution and in vivo, outperforming indocyanine green and many contemporary NIR‐II emitters. Through rational structural modifications across multiple length scales, the NIR‐II brightness is enhanced >5000× beyond alternative small molecules, featuring a minimum detectable dose of 0.65 n m in vivo. This performance, combined with synthetic accessibility and scalability, positions PDFT as a promising material for NIR‐II bionanotechnologies.
- Open Access
The Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment
Radiation has been utilized for a long time for the treatment of cancer patients. However, radiotherapy (RT) has many constraints, among which non-selectivity is the primary one. The implementation of nanoparticles (NPs) with RT not only localizes radiation in targeted tissue but also provides significant tumoricidal effect(s) compared to radiation alone. NPs can be functionalized with both biomolecules and therapeutic agents, and their combination significantly reduces the side effects of RT. NP-based RT destroys cancer cells through multiple mechanisms, including ROS generation, which in turn damages DNA and other cellular organelles, inhibiting of the DNA double-strand damage-repair system, obstructing of the cell cycle, regulating of the tumor microenvironment, and killing of cancer stem cells. Furthermore, such combined treatments overcome radioresistance and drug resistance to chemotherapy. Additionally, NP-based RT in combined treatments have shown synergistic therapeutic benefit(s) and enhanced the therapeutic window. Furthermore, a combination of phototherapy, i.e., photodynamic therapy and photothermal therapy with NP-based RT, not only reduces phototoxicity but also offers excellent therapeutic benefits. Moreover, using NPs with RT has shown promise in cancer treatment and shown excellent therapeutic outcomes in clinical trials. Therefore, extensive research in this field will pave the way toward improved RT in cancer treatment.
Open AccessThe Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment
Radiation has been utilized for a long time for the treatment of cancer patients. However, radiotherapy (RT) has many constraints, among which non-selectivity is the primary one. The implementation of nanoparticles (NPs) with RT not only localizes radiation in targeted tissue but also provides significant tumoricidal effect(s) compared to radiation alone. NPs can be functionalized with both biomolecules and therapeutic agents, and their combination significantly reduces the side effects of RT. NP-based RT destroys cancer cells through multiple mechanisms, including ROS generation, which in turn damages DNA and other cellular organelles, inhibiting of the DNA double-strand damage-repair system, obstructing of the cell cycle, regulating of the tumor microenvironment, and killing of cancer stem cells. Furthermore, such combined treatments overcome radioresistance and drug resistance to chemotherapy. Additionally, NP-based RT in combined treatments have shown synergistic therapeutic benefit(s) and enhanced the therapeutic window. Furthermore, a combination of phototherapy, i.e., photodynamic therapy and photothermal therapy with NP-based RT, not only reduces phototoxicity but also offers excellent therapeutic benefits. Moreover, using NPs with RT has shown promise in cancer treatment and shown excellent therapeutic outcomes in clinical trials. Therefore, extensive research in this field will pave the way toward improved RT in cancer treatment.
- Open Access
Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies
Hematological malignancies (HMs) are a heterogeneous group of blood neoplasia generally characterized by abnormal blood-cell production. Detection of HMs-specific molecular biomarkers (e.g., surface antigens, nucleic acid, and proteomic biomarkers) is crucial in determining clinical states and monitoring disease progression. Early diagnosis of HMs, followed by an effective treatment, can remarkably extend overall survival of patients. However, traditional and advanced HMs’ diagnostic strategies still lack selectivity and sensitivity. More importantly, commercially available chemotherapeutic drugs are losing their efficacy due to adverse effects, and many patients develop resistance against these drugs. To overcome these limitations, the development of novel potent and reliable theranostic agents is urgently needed to diagnose and combat HMs at an early stage. Recently, gold nanomaterials (GNMs) have shown promise in the diagnosis and treatment of HMs. Magnetic resonance and the surface-plasmon-resonance properties of GNMs have made them a suitable candidate in the diagnosis of HMs via magnetic-resonance imaging and colorimetric or electrochemical sensing of cancer-specific biomarkers. Furthermore, GNMs-based photodynamic therapy, photothermal therapy, radiation therapy, and targeted drug delivery enhanced the selectivity and efficacy of anticancer drugs or drug candidates. Therefore, surface-tuned GNMs could be used as sensitive, reliable, and accurate early HMs, metastatic HMs, and MRD-detection tools, as well as selective, potent anticancer agents. However, GNMs may induce endothelial leakage to exacerbate cancer metastasis. Studies using clinical patient samples, patient-derived HMs models, or healthy-animal models could give a precise idea about their theranostic potential as well as biocompatibility. The present review will investigate the theranostic potential of vectorized GNMs in HMs and future challenges before clinical theranostic applications in HMs.
Open AccessTheranostic Potentials of Gold Nanomaterials in Hematological Malignancies
Hematological malignancies (HMs) are a heterogeneous group of blood neoplasia generally characterized by abnormal blood-cell production. Detection of HMs-specific molecular biomarkers (e.g., surface antigens, nucleic acid, and proteomic biomarkers) is crucial in determining clinical states and monitoring disease progression. Early diagnosis of HMs, followed by an effective treatment, can remarkably extend overall survival of patients. However, traditional and advanced HMs’ diagnostic strategies still lack selectivity and sensitivity. More importantly, commercially available chemotherapeutic drugs are losing their efficacy due to adverse effects, and many patients develop resistance against these drugs. To overcome these limitations, the development of novel potent and reliable theranostic agents is urgently needed to diagnose and combat HMs at an early stage. Recently, gold nanomaterials (GNMs) have shown promise in the diagnosis and treatment of HMs. Magnetic resonance and the surface-plasmon-resonance properties of GNMs have made them a suitable candidate in the diagnosis of HMs via magnetic-resonance imaging and colorimetric or electrochemical sensing of cancer-specific biomarkers. Furthermore, GNMs-based photodynamic therapy, photothermal therapy, radiation therapy, and targeted drug delivery enhanced the selectivity and efficacy of anticancer drugs or drug candidates. Therefore, surface-tuned GNMs could be used as sensitive, reliable, and accurate early HMs, metastatic HMs, and MRD-detection tools, as well as selective, potent anticancer agents. However, GNMs may induce endothelial leakage to exacerbate cancer metastasis. Studies using clinical patient samples, patient-derived HMs models, or healthy-animal models could give a precise idea about their theranostic potential as well as biocompatibility. The present review will investigate the theranostic potential of vectorized GNMs in HMs and future challenges before clinical theranostic applications in HMs.
- Open Access
- 13 October 2021
- Published by MDPI AG in Polysaccharides
- Vol. 2 (4) , 795-816
Using Chitosan or Chitosan Derivatives in Cancer Therapy
Cancer is one of the major causes of death worldwide. Chemotherapeutic drugs have become a popular choice as anticancer agents. Despite the therapeutic benefits of chemotherapeutic drugs, patients often experience side effects and drug resistance. Biopolymers could be used to overcome some of the limitations of chemotherapeutic drugs, as well as be used either as anticancer agents or drug delivery vehicles. Chitosan is a biocompatible polymer derived from chitin. Chitosan, chitosan derivatives, or chitosan nanoparticles have shown their promise as an anticancer agent. Additionally, functionally modified chitosan can be used to deliver nucleic acids, chemotherapeutic drugs, and anticancer agents. More importantly, chitosan-based drug delivery systems improved the efficacy, potency, cytotoxicity, or biocompatibility of these anticancer agents. In this review, we will investigate the properties of chitosan and chemically tuned chitosan derivatives, and their application in cancer therapy.
- 13 October 2021
- Published by MDPI AG in Polysaccharides
- Vol. 2 (4) , 795-816
Open AccessUsing Chitosan or Chitosan Derivatives in Cancer Therapy
Cancer is one of the major causes of death worldwide. Chemotherapeutic drugs have become a popular choice as anticancer agents. Despite the therapeutic benefits of chemotherapeutic drugs, patients often experience side effects and drug resistance. Biopolymers could be used to overcome some of the limitations of chemotherapeutic drugs, as well as be used either as anticancer agents or drug delivery vehicles. Chitosan is a biocompatible polymer derived from chitin. Chitosan, chitosan derivatives, or chitosan nanoparticles have shown their promise as an anticancer agent. Additionally, functionally modified chitosan can be used to deliver nucleic acids, chemotherapeutic drugs, and anticancer agents. More importantly, chitosan-based drug delivery systems improved the efficacy, potency, cytotoxicity, or biocompatibility of these anticancer agents. In this review, we will investigate the properties of chitosan and chemically tuned chitosan derivatives, and their application in cancer therapy.
- Open Access
- 19 August 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (8) , 1295
Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment
Colorectal cancer (CRC) is one of the intimidating causes of death around the world. CRC originated from mutations of tumor suppressor genes, proto-oncogenes and DNA repair genes. Though platinum (Pt)-based anticancer drugs have been widely used in the treatment of cancer, their toxicity and CRC cells’ resistance to Pt drugs has piqued interest in the search for alternative metal-based drugs. Ruthenium (Ru)-based compounds displayed promising anticancer activity due to their unique chemical properties. Ru-complexes are reported to exert their anticancer activities in CRC cells by regulating different cell signaling pathways that are either directly or indirectly associated with cell growth, division, proliferation, and migration. Additionally, some Ru-based drug candidates showed higher potency compared to commercially available Pt-based anticancer drugs in CRC cell line models. Meanwhile Ru nanoparticles coupled with photosensitizers or anticancer agents have also shown theranostic potential towards CRC. Ru-nanoformulations improve drug efficacy, targeted drug delivery, immune activation, and biocompatibility, and therefore may be capable of overcoming some of the existing chemotherapeutic limitations. Among the potential Ru-based compounds, only Ru (III)-based drug NKP-1339 has undergone phase-Ib clinical trials in CRC treatment.
- 19 August 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (8) , 1295
Open AccessRuthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment
Colorectal cancer (CRC) is one of the intimidating causes of death around the world. CRC originated from mutations of tumor suppressor genes, proto-oncogenes and DNA repair genes. Though platinum (Pt)-based anticancer drugs have been widely used in the treatment of cancer, their toxicity and CRC cells’ resistance to Pt drugs has piqued interest in the search for alternative metal-based drugs. Ruthenium (Ru)-based compounds displayed promising anticancer activity due to their unique chemical properties. Ru-complexes are reported to exert their anticancer activities in CRC cells by regulating different cell signaling pathways that are either directly or indirectly associated with cell growth, division, proliferation, and migration. Additionally, some Ru-based drug candidates showed higher potency compared to commercially available Pt-based anticancer drugs in CRC cell line models. Meanwhile Ru nanoparticles coupled with photosensitizers or anticancer agents have also shown theranostic potential towards CRC. Ru-nanoformulations improve drug efficacy, targeted drug delivery, immune activation, and biocompatibility, and therefore may be capable of overcoming some of the existing chemotherapeutic limitations. Among the potential Ru-based compounds, only Ru (III)-based drug NKP-1339 has undergone phase-Ib clinical trials in CRC treatment.